Trial Profile
A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Suvorexant for Treatment-resistant Insomnia in Patients With Bipolar Disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Oct 2022
Price :
$35
*
At a glance
- Drugs Suvorexant (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- 03 Oct 2022 Status changed from recruiting to completed.
- 16 Mar 2021 Planned End Date changed from 1 Aug 2020 to 1 Aug 2021.
- 16 Mar 2021 Planned primary completion date changed from 1 Aug 2020 to 1 Aug 2021.